As per reports, Microsoft Corp. (MSFT) is working on an energy-saving update to its Xbox gaming consoles aiming to meet a 2030 deadline for its environmental goals. Starting Xbox Insiders, a subset of users will be automatically switched to a newly introduced energy-saving Shutdown option. When left idle consoles will use less power than in Sleep mode, which enables users to wake up devices and start gameplay more quickly. The Insider program is a small group of gamers that get an early look at features and content in development.
As more people get involved and gaming hardware uses more power, gaming has a substantial carbon footprint that is on track to increase.
Redmond, Washington-based American multinational technology company Microsoft (MSFT) develops, manufactures, licenses supports, and sells computer software, consumer electronics, personal computers, and related services. To learn more about Microsoft (MSFT) and to track their progress please visit the Vista Partners Coverage Page.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
Consider visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury.
READ THIS PROGRESS REPORT TOO…
On January 10, InMed Pharmaceuticals Inc. (Nasdaq: INM) issued a press release, which outlined their key accomplishments from 2022 and provided business update and catalysts for 2023 including the following interesting milestones for 2023:
- Complete Phase 2 clinical trial enrollment in Epidermolysis Bullosa in 1Q 2023
- Progress preclinical research in glaucoma in preparation for human trials
- Advance research using rare cannabinoids in treating neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s
REVIEWING InMed’s 2022 ACCOMPLISHMENTS
INM-755 in Epidermolysis Bullosa
Activated 11 clinical trial sites in seven countries for the Phase 2 study
Expanded from adult subjects to include adolescents following independent review of early safety data
Progressed clinical trial with enrollment and treatment of 15 patients, with the 16th patient enrolled for treatment in early January 2023
To review the balance of the this report please follow us by clicking here!